• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

腹腔内化疗给药的端口和并发症。

Ports and complications for intraperitoneal chemotherapy delivery.

机构信息

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology and Women's Health, Saint Louis University School of Medicine, MO, USA.

出版信息

BJOG. 2012 Jan;119(2):150-9. doi: 10.1111/j.1471-0528.2011.03179.x. Epub 2011 Oct 21.

DOI:10.1111/j.1471-0528.2011.03179.x
PMID:22017885
Abstract

Intraperitoneal access ports are essential to the delivery of chemotherapy agents into the peritoneal cavity of women with ovarian cancer, but their malfunction and adverse effects are frequently responsible for the failure to complete planned therapy. Complications, such as obstruction of the catheter, infection, leakage, rotation, retraction, and pain, together with bowel and vaginal perforation, cause delays in treatment, patient suffering and the expenditure of medical resources. A wide variety of ports have been used, including vascular access devices and intraperitoneal access devices. This paper reviews the development and use of ports for intraperitoneal chemotherapy, their complications and reported methods of prevention.

摘要

腹腔内置管是将化疗药物输送到卵巢癌女性腹腔的重要手段,但它们经常出现故障和不良反应,导致无法完成计划治疗。并发症,如导管阻塞、感染、泄漏、旋转、回缩和疼痛,以及肠穿孔和阴道穿孔,会导致治疗延误、患者痛苦和医疗资源浪费。已经使用了各种各样的端口,包括血管接入装置和腹腔接入装置。本文回顾了用于腹腔化疗的端口的发展和使用、它们的并发症以及已报道的预防方法。

相似文献

1
Ports and complications for intraperitoneal chemotherapy delivery.腹腔内化疗给药的端口和并发症。
BJOG. 2012 Jan;119(2):150-9. doi: 10.1111/j.1471-0528.2011.03179.x. Epub 2011 Oct 21.
2
The port: delivering intraperitoneal chemotherapy in ovarian cancer.端口:用于卵巢癌腹腔内化疗
Todays OR Nurse. 1992 Sep;14(9):11-8.
3
Problems associated with the administration of intraperitoneal therapy using the Port-A-Cath system.使用Port-A-Cath系统进行腹腔内治疗相关的问题。
Oncol Nurs Forum. 1990 Jan-Feb;17(1):75-80.
4
Complications associated with intraperitoneal chemotherapy catheters.与腹腔内化疗导管相关的并发症。
Gynecol Oncol. 2001 Apr;81(1):77-81. doi: 10.1006/gyno.2000.6108.
5
The Groshong catheter as an intraperitoneal access device in the treatment of ovarian cancer patients.格罗雄导管作为一种用于治疗卵巢癌患者的腹腔内通路装置。
Gynecol Oncol. 1993 Sep;50(3):291-3. doi: 10.1006/gyno.1993.1213.
6
Celsite port and catheter as an intraperitoneal access device in the treatment of ovarian cancer.Celsite端口和导管作为一种腹腔内接入装置用于治疗卵巢癌。
J Surg Oncol. 2000 Jul;74(3):223-6. doi: 10.1002/1096-9098(200007)74:3<223::aid-jso14>3.0.co;2-q.
7
Intraperitoneal chemotherapy for patients with advanced epithelial ovarian cancer: a review of complications and completion rates.晚期上皮性卵巢癌患者的腹腔内化疗:并发症及完成率综述
Gynecol Oncol. 2008 Feb;108(2):342-7. doi: 10.1016/j.ygyno.2007.10.004. Epub 2007 Nov 7.
8
Outcomes associated with different intraperitoneal chemotherapy delivery systems in advanced ovarian carcinoma: a single institution's experience.晚期卵巢癌中不同腹腔内化疗给药系统的相关结局:单机构经验
Gynecol Oncol. 2009 Sep;114(3):420-3. doi: 10.1016/j.ygyno.2009.05.036. Epub 2009 Jun 26.
9
Complications relating to intraperitoneal administration of cisplatin or carboplatin for ovarian carcinoma.顺铂或卡铂腹腔内给药治疗卵巢癌的相关并发症。
Gynecol Oncol. 2000 Dec;79(3):420-3. doi: 10.1006/gyno.2000.5979.
10
Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study.在III期卵巢癌和原发性腹膜癌最佳分期患者中静脉化疗与腹腔化疗对比试验的腹腔导管结局:一项妇科肿瘤学组研究
Gynecol Oncol. 2006 Jan;100(1):27-32. doi: 10.1016/j.ygyno.2005.11.013.

引用本文的文献

1
Long-term intraperitoneal access with description of a new access catheter.长期腹腔通路及一种新型通路导管的描述
J Surg Oncol. 2024 Nov;130(6):1390-1394. doi: 10.1002/jso.27843. Epub 2024 Aug 25.
2
Hyperthermic Intraperitoneal Chemotherapy plus Intravenous Chemotherapy of Paclitaxel with or without Sintilimab in Gastric Cancer: A Comparative Study.热灌注腹腔化疗联合紫杉醇静脉化疗加或不加信迪利单抗治疗胃癌的比较研究
J Oncol. 2022 Feb 22;2022:3054485. doi: 10.1155/2022/3054485. eCollection 2022.
3
Enhanced anti-tumor efficacy and safety with metronomic intraperitoneal chemotherapy for metastatic ovarian cancer using biodegradable nanotextile implants.
采用生物可降解纳米纤维植入物进行节拍式腹腔化疗治疗转移性卵巢癌的增效减毒作用。
J Control Release. 2019 Jul 10;305:29-40. doi: 10.1016/j.jconrel.2019.05.022. Epub 2019 May 17.
4
Morphology of the peritoneal cavity and pathophysiological consequences.腹膜腔的形态学及病理生理后果。
Pleura Peritoneum. 2016 Dec 1;1(4):193-201. doi: 10.1515/pp-2016-0023. Epub 2017 Jan 10.
5
Utilization of an Alternative Docetaxel-based Intraperitoneal Chemotherapy Regimen in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma: A Continued Need for Ovarian Cancer Patients.在卵巢癌、输卵管癌或原发性腹膜癌患者中应用替代多西紫杉醇腹腔化疗方案:卵巢癌患者的持续需求。
Am J Clin Oncol. 2019 Jan;42(1):12-16. doi: 10.1097/COC.0000000000000468.
6
Multiplex profiling identifies distinct local and systemic alterations during intraperitoneal chemotherapy for ovarian cancer: An NRG Oncology/Gynecologic Oncology Group Study.多重分析鉴定卵巢癌腹腔化疗期间不同的局部和全身改变:一项NRG肿瘤学/妇科肿瘤学组研究。
Gynecol Oncol. 2017 Jul;146(1):137-145. doi: 10.1016/j.ygyno.2017.04.008. Epub 2017 May 5.
7
Distance from a Comprehensive Cancer Center: A proxy for poor cervical cancer outcomes?与综合癌症中心的距离:宫颈癌预后不良的一个指标?
Gynecol Oncol. 2016 Dec;143(3):617-621. doi: 10.1016/j.ygyno.2016.10.004. Epub 2016 Oct 6.
8
Cited rationale for variance in the use of primary intraperitoneal chemotherapy following optimal cytoreduction for stage III ovarian carcinoma at a high intraperitoneal chemotherapy utilization center.在一个高腹腔内化疗利用率中心,针对III期卵巢癌进行最佳细胞减灭术后原发性腹腔内化疗使用差异的引用理由。
Gynecol Oncol. 2016 Jul;142(1):13-18. doi: 10.1016/j.ygyno.2016.05.015. Epub 2016 May 21.
9
Management of recurrent epithelial ovarian cancer.复发性上皮性卵巢癌的管理
Gland Surg. 2014 Aug;3(3):198-202. doi: 10.3978/j.issn.2227-684X.2013.10.01.